First Quarter 2022 Results

Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world

NYSE: MRK

Achieved significant regulatory approvals and clinical advancements across research pipeline

Broad and growing late-stage cardiovascular pipeline and portfolio

Delivering commercial success across broad set of growth drivers, including KEYTRUDA, GARDASIL, GARDASIL 9 and Animal Health

Strong Q1 performance reflects continued business momentum

Worldwide Sales	GAAP EPS	Non-GAAP EPS
$15.9B	$1.70	$2.14

Updated 2022 financial outlook underscores ongoing success

$56.9B to $58.1B	$5.90 to $6.02	$7.24 to $7.36

Sales

KEYTRUDA® (pembrolizumab) Injection 100 mg

Grew ▲ 23% to $4.8B

GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]

GARDASIL 9® Human Papillomavirus 9-valent Vaccine, Recombinant

Grew ▲ 59% to $1.5B

Lagevrio* molnupiravir

$3.2B

MERCK Animal Health

Grew ▲ 4% to $1.5B

"We successfully delivered across our key strategic priorities and achieved strong top and bottom-line growth. Our robust first quarter performance was driven by significant clinical advancements in our research pipeline and our ability to effectively execute commercially across a broad set of key growth drivers. We remain focused on driving our strategy, which is led by science, and are confident in the durability of our growth prospects, as we continue to provide value for patients, shareholders and all our stakeholders today and well into the future."

Rob Davis
Chief Executive Officer and President, Merck

*LAGEVRIO is not approved, but is authorized for emergency use by the FDA.